Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »
Most viewed

Hot Topics

12th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum


Lipoprotein(a) in the spotlight

Professor Børge Nordestgaard (University of Copenhagen, Denmark) appraises the evidence

Watch the webcast


Lp(a): Findings in ODYSSEY OUTCOMES

Professor Greg Schwartz (University of Colorado School of Medicine, Aurora, USA) discusses the latest evidence

Watch the webcast


How much do you have to reduce Lp(a) to achieve significant clinical benefit?

Professor Henry Ginsberg (University of Columbia, New York, USA) draws on the data to give his view

Watch the webcast


From the Editors

Looking beyond LDL: PCSK9 inhibition and remnants

Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles

Read the report


Other related reports:
Did someone say “Beyond LDL-cholesterol”?
Read the report
New EAS Consensus Panel statement: an Opus for LDL-driven mechanisms in atherosclerosis
Read the report

ACC 2017

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology